Who
Stephen Paul O'Brien
Principal Accounting Officer
Company insider
Files Form 4 as: Principal Accounting Officer, Tvardi Therapeutics.
In numbers
- Trades disclosed
- 6
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 15 Apr 2025
- Last trade
- 29 Jan 2026
- Last filed
- 2 Feb 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Jan 2026filed 2 Feb 2026 | TVRD Tvardi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 29 Jan 2026filed 2 Feb 2026 | TVRD Tvardi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 16 Dec 2025filed 18 Dec 2025 | TVRD Tvardi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 17 Apr 2025filed 21 Apr 2025 | TVRD Tvardi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,213 at $0.00 | filing |
| 15 Apr 2025filed 17 Apr 2025 | TVRD Tvardi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,399 | filing |
| 15 Apr 2025filed 17 Apr 2025 | TVRD Tvardi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,352 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.